1. A method of reducing the activity of an activated kinase of a control point of a cell cycle, where the specified method comprises exposing the specified kinase to a control point of a peptide, where the specified peptide sequence is SEQ ID NO: 2, 3, 5, 6, 8, or 10.2. The method of claim 1, wherein said peptide is SEQ ID NO: 10.3. The method of claim 1, wherein said peptide is SEQ ID NO: 2, 3, 5, 6, or 8.4. The method of claim 1, wherein said peptide is amidated at its carboxy terminus. The method of claim 1, wherein said control point kinase is a control point kinase-2 (Chk2). The method of claim 1, wherein said checkpoint kinase is activated as a result of DNA damage caused by ultraviolet radiation. The method of claim 1, wherein said checkpoint kinase is present in human skin. A method of treating mammalian skin to reduce toxicity associated with exposure to ultraviolet light, wherein said method comprises applying a peptide to said skin, wherein said peptide sequence is SEQ ID NO: 2, 3, 5, 6, 8, or 10.9. The peptide composed by the sequence of SEQ ID NO: 3, 5, 6, 8 or 10.10. The peptide of claim 9, wherein said peptide is SEQ ID NO: 10.11. The peptide of claim 9, wherein said peptide is SEQ ID NO: 3, 5, 6, or 8.12. The peptide of claim 9, wherein said peptide is amidated at its carboxy terminus. The peptide of claim 12, wherein said peptide is SEQ ID NO: 10.14. The peptide of claim 12, wherein said peptide is SEQ ID NO: 3, 5, 6, or 8.15. A composition comprising the peptide of claim 9 and a pharmaceutically acceptable carrier. The composition of claim 15, wherein the composition is in the form of an aerosol, emulsion, liquid, lotion,1. Способ снижения активности активированной киназы контрольной точки клеточного цикла, где указанный способ включает воздействие на указанную киназу контрольной точки пептида, где указанная пептидная последовательность представляет собой SEQ ID NO:2, 3, 5, 6, 8 или 10.2. Способ по п.1, где указанный пептид представляет собой SEQ I
